Online, Digital

Live,

Event,

US,

ZIP: 10000

Phone: +442031418700

With the recent clinical validation by BMS, LAG-3 combinations are spearheading the next wave of immune checkpoint inhibitors. As such, there has been an explosion of interest and high-scale investment into this exciting space.

Arriving at a critical point for LAG-3 development, the first ever LAG-3 Targeted Drug Development Summit is the definitive industry-led event focused on propelling this next generation inhibitor to clinical use.

Ensure your LAG-3 program reaches full clinical potential through hearing from experts discuss:

The progress that has been made and challenges faced in bispecific antibody based approaches

Improving combination therapy regimens

Better understanding the underpinning biology of LAG-3 as a cancer target

Utilizing biomarkers to understand the interplay between PD-1 and LAG-3

Join translational and clinical experts in LAG-3 development from Roche, BMS, F-STAR, Regeneron, Immutep, Macrogenics, University of Pittsburgh and more.

URLs:
Tickets: https://go.evvnt.com/900993-2?pid=4528
Brochure: https://go.evvnt.com/900993-3?pid=4528

Prices:
Drug Developer Pricing - 3 Day Pass - (Conference + Workshop Day): USD 2448.00,
Drug Developer Pricing - 2 Day Pass - (Conference Only): USD 2099.00,
Solution Provider Pricing - 3 Day Pass - (Conference + Workshop Day): USD 2998.00,
Solution Provider Pricing - 2 Day Pass - (Conference Only): USD 2599.00
 

Andrew Pierce Vice President - Translational Biology Crescendo Biologics, Ashwin Somasundaram Professor University of Pittsburgh Medical Center, Creg Workman Research Assistant and Officer University of Pittsburgh, Ella Ioffe Director Regeneron Pharmaceuticals, Frederic Triebel Chief Scientific Officer and Chief Medical Officer Immutep, Giuseppe Gullo Clinical Lead Regeneron Pharmaceuticals, Jessica Chacon Assistant Professor Texas Tech University Health Sciences Center, Jon Piganelli Associate Professor School of Medicine University of Pittsburgh, Laura Codari Deak Team and Research Project Leader, Principal Scientist Roche Innovation Center, Marc Voigt Chief Executive Officer Immutep, Michelle Morrow VP, Preclinical Translational Pharmacology F-Star Biotechnology, Paul Moore Vice President - Immunology and Cell Biology MacroGenics, Richard Wu Professor Ohio State University, Sarah Lauder Research Associate Cardiff University, Segundo Gonzalez Leader Universidad de Oviedo, Shuqi Zeng Senior Director Medical Epimab Biotherapeutics, Xiaobo Mao Associate Professor Johns Hopkins School of Medicine, Yvonne Saenger Director of Melanoma Immunotherapy Columbia University

HEALTH AND MEDICINE CONFERENCES